166 related articles for article (PubMed ID: 22373943)
1. Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation.
Gold AB; Wileyto EP; Lori A; Conti D; Cubells JF; Lerman C
Neuropsychopharmacology; 2012 Jun; 37(7):1683-8. PubMed ID: 22373943
[TBL] [Abstract][Full Text] [Related]
2. Mediators of the effect of nicotine pre-treatment on quitting smoking.
Hajek P; Lewis S; Munafo M; Lindson N; Coleman T; Aveyard P;
Addiction; 2018 Dec; 113(12):2280-2289. PubMed ID: 30066385
[TBL] [Abstract][Full Text] [Related]
3. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
[TBL] [Abstract][Full Text] [Related]
5. Nicotine replacement therapy for smoking cessation.
Stead LF; Perera R; Bullen C; Mant D; Hartmann-Boyce J; Cahill K; Lancaster T
Cochrane Database Syst Rev; 2012 Nov; 11():CD000146. PubMed ID: 23152200
[TBL] [Abstract][Full Text] [Related]
6. Nicotine replacement therapy for smoking cessation.
Silagy C; Mant D; Fowler G; Lancaster T
Cochrane Database Syst Rev; 2000; (3):CD000146. PubMed ID: 10908462
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Bailey SR; Crew EE; Riske EC; Ammerman S; Robinson TN; Killen JD
Paediatr Drugs; 2012 Apr; 14(2):91-108. PubMed ID: 22248234
[TBL] [Abstract][Full Text] [Related]
8. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
9. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
10. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
11. Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods.
Przulj D; Wehbe L; McRobbie H; Hajek P
Addiction; 2019 Mar; 114(3):515-522. PubMed ID: 30370685
[TBL] [Abstract][Full Text] [Related]
12. Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?
Panagiotou OA; Schuit E; Munafò MR; Bennett DA; Bergen AW; David SP
Nicotine Tob Res; 2019 Aug; 21(9):1289-1293. PubMed ID: 30690475
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic investigation of smoking cessation treatment.
Lerman C; Shields PG; Wileyto EP; Audrain J; Pinto A; Hawk L; Krishnan S; Niaura R; Epstein L
Pharmacogenetics; 2002 Nov; 12(8):627-34. PubMed ID: 12439223
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.
Perkins KA; Lerman C; Mercincavage M; Fonte CA; Briski JL
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2608-12. PubMed ID: 19755656
[TBL] [Abstract][Full Text] [Related]
15. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
[TBL] [Abstract][Full Text] [Related]
16. Success of smoking cessation interventions during pregnancy.
Bérard A; Zhao JP; Sheehy O
Am J Obstet Gynecol; 2016 Nov; 215(5):611.e1-611.e8. PubMed ID: 27402053
[TBL] [Abstract][Full Text] [Related]
17. Smoking cessation interventions for smokers with current or past depression.
van der Meer RM; Willemsen MC; Smit F; Cuijpers P
Cochrane Database Syst Rev; 2013 Aug; (8):CD006102. PubMed ID: 23963776
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
Leventhal AM; David SP; Brightman M; Strong D; McGeary JE; Brown RA; Lloyd-Richardson EE; Munafò M; Uhl GR; Niaura R
Pharmacogenomics J; 2012 Feb; 12(1):86-92. PubMed ID: 20661272
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from an outpatient smoking-cessation clinic.
Roth MT; Andrus MR; Westman EC
Pharmacotherapy; 2005 Feb; 25(2):279-88. PubMed ID: 15767242
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders.
Evins AE; Culhane MA; Alpert JE; Pava J; Liese BS; Farabaugh A; Fava M
J Clin Psychopharmacol; 2008 Dec; 28(6):660-6. PubMed ID: 19011435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
